source
- BMS beats Q2 forecasts and lifts 2026 outlook despite delays in Cobenfy and milvexian dataBMS reported second‑quarter revenue of $12.97 billion, topping analysts' estimate of $11.73 billion, and earnings per share of $2.04, well above the $1.60 consensus. The strong results prompted the…
- Ebola cases approach key milestone as vaccine candidates draw near completionThe latest update on the Ebola outbreak indicates that the number of cases is approaching a significant threshold, while vaccine development efforts are reported to be close to delivering a usable…